Omeros' performance has consistently failed to meet expectations, raising concerns about its future prospects. Read more to ...

The case involved a 59-year-old man with stage IIIA right lung adenocarcinoma who underwent surgery in 2021, followed by ...

A study published this week in the peer-reviewed journal Scientific Reports examined the long-term impacts of having shingles ...

The FDA is expected to decide on treatments for acromegaly, edema, HSCT-associated thrombotic microangiopathy, multiple sclerosis, and spinal muscular atrophy. The FDA is reviewing a nasal spray ...

Omeros’ efforts to get its transplant drug to market have already suffered one FDA rejection. | Omeros’ efforts to get its ...

In late May, a patient died after receiving Rocket Pharmaceuticals' investigational gene therapy for Danon disease, spurring ...

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended ...

The FDA has freed Rocket Pharmaceuticals from a clinical hold, giving the gene therapy developer permission to take flight with its pivotal cardiomyopathy disorder trial. | The FDA has freed Rocket ...

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the ...

Q2 2025 Earnings Call Transcript August 14, 2025 Omeros Corporation beats earnings expectations. Reported EPS is $-0.53, ...

3.3 Vascular injury and microangiopathy Diabetes exerts profound detrimental effects on cerebrovascular health, precipitating vascular injury and microvascular pathologies closely associated with ...